Présentation

P4-1 Introduction: Why is innovation in clinical trials needed now?

Peter Dull

Auteurs

Langues

  • Anglais

Année de publication

2025

Type

Présentation

Catégories

GVIRF-2025

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
GVIRF 2025 Call for Abstracts2024Poster/infographicAnglais
GVIRF 2025 Detailed AgendaGVIRF Secretariat2025WebinarAnglais
GVIRF 2025: Opening Remarks - VIDEOGVIRF Secretariat2025WebinarAnglais
Keynote: Dr Akira HommaAkira Homma2025PresentationAnglais
Keynotes: Akira Homma and Aurelia Nguyen - VIDEOAurélia Nguyen, Akira Homma2025WebinarAnglais
Meeting Summary: Global Vaccine and Immunization Research Forum, 2025 (preprint)Angela Hwang, Kristen Earle, Erin Grace Sparrow, Peter Dull, Birgitte K. Giersing2026Journal articleAnglais
P1-1 Innovations in vaccine discoveryGalit Alter2025PresentationAnglais
P1-2 Innovation in vaccine developmentAndrew Pollard2025PresentationAnglais
P1-3 Delivering vaccines: Vaccine innovation ecosystem past, present, and futureAnne Schuchat2025PresentationAnglais
P1-4 Vaccination overview in BrazilEder Gatti2025PresentationAnglais
P1: The vaccine innovation ecosystem, past, present, and future - VIDEOGVIRF Secretariat2025WebinarAnglais
P2-1 Pathogen prioritization at the global level: WHO Global Priority Endemic Pathogens for Vaccine R&DMateusz Hasso-Agopsowicz2025PresentationAnglais
P2-2 Prioritizing pathogens with epidemic and pandemic potentialJakob Cramer2025PresentationAnglais
P2-3 Setting R&D Priorities – Bio-Manguinhos’ PerspectivesRicardo de Godoi2025PresentationAnglais
P2-4 Development of vaccines for global use: Role of the vaccine industryLuis Jodar2025PresentationAnglais
P2: What to develop, what to deliver? Priority setting along the value chain - VIDEOGVIRF Secretariat2025WebinarAnglais
P3-1 The Value of Health R&D –The Return on InvestmentNick Chapman2025PresentationAnglais
P3-2 The infectious diseases vaccines R&D financing landscape​: An Industrial perspective​Nick Jackson2025PresentationAnglais
P3-3 The CEPI R&D Funding ModelAurélia Nguyen2025PresentationAnglais
P3: How do we sustain investment in R&D? - VIDEOGVIRF Secretariat2025WebinarAnglais
P4-1 Introduction: Why is innovation in clinical trials needed now?Peter Dull2025PresentationAnglais
P4-2 Clinical immunobridging strategy to support licensure of preventive vaccinesMarion Gruber2025PresentationAnglais
P4-3 A systematic approach to identification of correlates of protectionDeborah King2025PresentationAnglais
P4-4 Vaccine efficacy evidence generation in outbreaksJakob Cramer2025PresentationAnglais
P4: Innovation in clinical trials - VIDEOGVIRF Secretariat2025WebinarAnglais
P5-1 Overview of arbovirus vaccinesMelanie Saville2025PresentationAnglais
P5-2 What is the current state of dengue vaccine development and new technologies?Esper Kallas2025PresentationAnglais
P5-3 Approved Chikungunya vaccinesMarco Cavaleri2025PresentationAnglais
P5-4 Yellow Fever Vaccination: Fractional dosing and one versus two life-time dosesPatricia Mouta Nunes de Oliveira2025PresentationAnglais
P5: Arbovirus vaccines, including dengue and chikungunya - VIDEOGVIRF Secretariat2025WebinarAnglais
P6-1 What have we learned in the COVID19 pandemic?Ricardo Tostes Gazzinelli2025PresentationAnglais
P6-2 Global and Regional Vaccine R&D UpdateMaria Elena Bottazzi2025PresentationAnglais
P6-3 mRNA vaccine production capacity building in Latin AmericaTomás Pippo2025PresentationAnglais
P6-3 mRNA vaccine production capacity building in Latin AmericaTomás Pippo2025WebinarEspagnol
P6-4 Case studies for clinical trial capacity in the regionSue Ann Costa Clemens 2025PresentationAnglais
P6: Vaccine R&D Updates - VIDEOGVIRF Secretariat2025WebinarAnglais
P7-1 Predicting infectious disease responses to climate changeSonia Altizer2025PresentationAnglais
P7-2 Oceans, climate and health: The cholera paradigmRita Colwell2025PresentationAnglais
P7-3 Climate change and vaccine-preventable diseasesNeil Ferguson2025PresentationAnglais
P7: Rising to the challenges of climate change - VIDEOGVIRF Secretariat2025WebinarAnglais
P8-1 Equitable and sustainable access to new vaccines: Where are we and what will it take?Tara Prasad2025PresentationAnglais
P8-2 Regional Revolving FundsSantiago Cornejo2025PresentationAnglais
P8: Equitable and sustainable access to new vaccines: where are we and what will it take?GVIRF Secretariat2025WebinarAnglais
P9: Strategies to safeguard vaccine research and development for the worldGVIRF Secretariat2025WebinarAnglais
W1-1 Trends in vaccine technology innovationsJorge Kalil2025PresentationAnglais
W1-2 Novel adjuvants and mucosal vaccination strategiesEd Lavelle2025PresentationAnglais
W1-3 Oral delivery of biologicsGiovanni Traverso2025PresentationAnglais
W1-4 Glycoconjugate Vaccines: Molecular architecture and controlled heterogeneityJohn Hennessey2025PresentationAnglais
W1-5 Novel Vaccines Technologies: Moving to the ClinicHana El Sahly2025PresentationAnglais
W1: Innovation in vaccine technology platforms and administration technologies - VIDEOGVIRF Secretariat2025WebinarAnglais
Log in to vote

Ajouté par: Angela Hwang

Ajouté le: 2025-04-07 17:37:57

Consultations: 949

Liens

Fichier téléchargé

P4-1 DULL.pdf

Cliquez pour télécharger

Signaler un problème

Ajouter une ressource